Last updated: November 25, 2024
Sponsor: Karolinska Institutet
Overall Status: Completed
Phase
N/A
Condition
Cystic Fibrosis
Scar Tissue
Lung Disease
Treatment
linoleic acid supplementation
oleic acid supplementation
Clinical Study ID
NCT04531410
2020-02871
Ages 5-15 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Two mutations related to severe clinical status such as dF508, or other stopmutations or class II mutations. Severe status includes pancreatic insufficiency
Exclusion
Exclusion Criteria:
- Liver cirrhosis and/or portal hypertension, transplantation or on transplantationlist, intake of lipid supplements the latest 2 months
Study Design
Total Participants: 50
Treatment Group(s): 2
Primary Treatment: linoleic acid supplementation
Phase:
Study Start date:
October 25, 2021
Estimated Completion Date:
November 05, 2024
Study Description
Connect with a study center
Centro Regionale di Supporto per la Fibrosei Cistica, ASST Spedali civili, Univ of Brescia
Brescia, Brescia - Lombardia 25123
ItalySite Not Available
Università degli Studi di Milan
Milan,
ItalySite Not Available
Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital
Oslo,
NorwaySite Not Available
Poznan University of Medical Sciences
Poznań,
PolandSite Not Available
Center of Cystic fibrosis, Dept of Pediatrics, Lund University Hospital
Lund, Skåne 22242
SwedenSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.